Antiviral Drugs

NanoViricides Receives Regulatory Approval for Phase II MPox Trial in Democratic Republic of Congo

NanoViricides Receives Regulatory Approval for Phase II MPox Trial in Democratic Republic of Congo

NanoViricides has received regulatory approval to begin Phase II clinical trials for its broad-spectrum antiviral drug NV-387 to treat MPox in the Democratic Republic of Congo, representing a potential breakthrough in antiviral therapy.

November 10, 2025
NanoViricides Reveals Breakthrough Antiviral Platform at BIO International Convention

NanoViricides Reveals Breakthrough Antiviral Platform at BIO International Convention

NanoViricides will showcase its novel NV-387 broad-spectrum antiviral drug candidate, which demonstrates promising preclinical efficacy against multiple viral infections, potentially revolutionizing viral treatment approaches.

May 28, 2025
NanoViricides Secures Ethics Approval for Mpox Phase II Trial in Democratic Republic of Congo

NanoViricides Secures Ethics Approval for Mpox Phase II Trial in Democratic Republic of Congo

NanoViricides has received ethical clearance to conduct a Phase II clinical trial for NV-387, a broad-spectrum antiviral drug targeting Mpox, signaling potential progress in viral disease treatment strategies.

May 8, 2025